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HLA antibodies are primary causes of transplant rejection; they recognize epitopes that 
can be structurally defined by eplets. There are many reviews about HLA epitope-based 
matching in transplantation. This article describes some personal reflections about epi-
topes including a historical perspective of HLA typing at the antigen and allele levels, the 
repertoires of antibody-verified HLA epitopes, the use of HLAMatchmaker in determining 
the specificities of antibodies tested in different assays, and, finally, possible strategies to 
control HLA antibody responses.
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iNTRODUCTiON
It is now universally accepted that HLA matching affects transplant outcome and that HLA anti-
bodies are primary causes of transplant rejection. HLA antibodies recognize epitopes, which can 
be structurally defined by eplets, i.e., small configurations of polymorphic amino acid configura-
tions on the HLA molecular surface. This article addresses the concept that HLA matching can 
be determined at the epitope level. It is not intended as an extensive review of the literature; the 
www.HLAMatchmaker.net website has numerous epitope-related publications, and there are several 
review articles (1–4). Rather, this paper offers some recent reflections about the role of HLA epitopes 
in histocompatibility.
ePiTOPeS AND A HiSTORiCAL PeRSPeCTive OF  
SeROLOGiCAL HLA TYPiNG
HLA emerged from observations by a few investigators including Rose Payne, Jon van Rood, and 
Jean Dausset who during the early 1960s studied sera with leukocyte antibodies in patients with 
non-hemolytic transfusion reactions and in women after pregnancies (5). Most reactivity patterns 
with leukocyte panels were uninterpretable, until international HLA workshops were organized 
whereby collaborating laboratories adapted the so-called microdrop complement-dependent lym-
phocytotoxicity technique developed by Terasaki and McClelland (6). Sera could be grouped into 
non-overlapping clusters with highly correlated reactivity patterns, and this permitted assignments 
of specificities such as HLA-A1, A2, B5, and B7. Such clusters served as reference standards for 
serological HLA typing reagents. Later on, subclusters of sera identified the so-called splits such as 
A10 was split into A25 and A26, and B16 was split into B38 and B39. Continued workshop efforts 
led to a set of HLA-class I specificities also called antigens that could be identified serologically with 
the complement-dependent lymphocytotoxicity technique. Most HLA antigens were defined with 
the so-called monospecific sera, but many others could be only identified from reactivity patterns of 
selected sera on typing trays.
Yunis and Amos first proposed the HLA-D locus from cellular assays based on mixed lymphocyte 
reactivity (7). Specific Dw determinants were later identified with HLA-D homozygous typing 
TABLe 1 | Specificities of commonly used serological typing reagents and their corresponding eplets.
Serological specificity Corresponding eplet Serological specificity Corresponding eplet Serological specificity Corresponding eplet
Al 163RG B18 30G DR7 + 9 78V2
A1 + A36 44KM2 B18 + B35 44RT DR8 25YRF
A2 66RKH B27 71KA DR8 + 12 16Y
A2 + A28 142MT B40 44RK DR9 13FEY
A2 + A69 107W B44 199V DR10 40YD2
A3 161D B48 245TA DR11 57DE
A9 66GKH Bw4 82LR DR12 37L
A10 149TAH Bw6 80ERN DR13 71DEA
A11 151AHA Cwl 6K DR14 57AA
A25 + A32 76ESI Cw2 211T DR15 71A
A29 62LQ Cw3 173K DR17 26TYD
A30 152RW Cw4 17WR DR51 96EN3
A30 + A31 56R Cw5 + 8 138K DR52 98Q
A31 + A33 73ID Cw7 193PL DR53 48YQ6
A68 245VA DR1 12LKF2 DQ1 52PQ2
B5 + B35 193PV DR1 + 10 13FEL DQ2 45GE3
B7 177DK DR1 + 51 96EV DQ3 55PP
B8 + Cw7 9D DR2 142M2 DQ4 56L2
B12 167ES DR3 74R DQ5 74SR3
B13 144QL DR4 96Y2 DQ6 125G
B15 163LW DR3 + 6 31YYFH DQ7 45EV
B16 158T DR7 25Q3 DQ8 56PPA
B17 71SA DQ7 + 9 56PPD
Eplet descriptions are according to HLAMatchmaker (www.epitopes.net). The number represents the sequence location of one of the polymorphic residues annotated with standard 
single letters. Some eplets have subscripted numbers indicating additional residue configurations in other locations.
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cells and primed alloreactive lymphocytes. Certain sera had anti-
bodies with blocking effects on lymphocyte reactivity and with 
complement-dependent cytotoxicity assays using B-cells, and it 
was possible to identify serum clusters specific for serologically 
defined Dw related or DR antigens now referred to as DR1, 
DR2, DR3, etc. (8). Subclusters of sera also identified “splits” 
such as DR11 and DR12 of DR5.
HLA workshop studies during the 1980s identified clusters of 
sera specific for the DRB3/4/5-encoded antigens DR51, DR52, 
and DR53 and the DQB antigens DQ1, DQ2, DQ3, and DQ4 and 
again subclusters of sera demonstrated “splits” such as the DQ5 
and DQ6 splits of DQ1.
As noted above, serological typing was primarily based on 
reactivities of specific antisera with antigens. Since it is now 
recognized that HLA antibodies are specific for epitopes rather 
than antigens, it seems obvious that HLA-typing sera must 
recognize distinct epitopes uniquely present on serologically 
defined antigens. The HLAMatchmaker analysis has shown 
that many HLA antigens detected by the so-called monospe-
cific or duospecific sera have unique eplets, and almost all of 
them are recorded in the International HLA Epitope Registry 
(http://www.epregistry.com.br) as experimentally verified 
with informative antibodies (Table  1). In other words, anti-
A1 antibodies actually recognize the 163RG eplet, which is 
only found on A1, anti-B7 antibodies are specific for 177DK 
uniquely present on B7, and anti-Cw1 antibodies recognize 
an epitope defined by 6K. Several serological splits can be 
explained by eplets paired with other residue configurations. 
For instance, A10 corresponds to 149TAH, whereas the A25 
and A26 splits represent 149TAH + 80I and 149TAH + 80N, 
respectively. Similarly, the B38 and B39 splits of B16 are defined 
by antibodies specific for epitopes defined by the 158T + 80I 
and 158T +  80N pairs, respectively. Also, Table 1 illustrates 
that most serologically defined DR and DQ antigens have 
uniquely distinct eplets. The cellularly defined DP specificities 
[originally called SB (9)] do not have unique eplets, and this 
explains why they cannot be readily determined serologically 
with monospecific sera.
The information in Table 1 is based on molecular structure 
and amino acid sequence information of HLA antigens which did 
not emerge until after the late 1980s. Before that, the specificities 
of serum clusters in the early workshops could only be desig-
nated with an arbitrary notation system of serologically defined 
antigens, although we can now readily see that they reflect the 
recognition of distinct epitopes. Accordingly, the HLA antigen-
matching effect on transplant outcome can be reinterpreted as 
actually demonstrating the influence of matching for epitopes, 
albeit limited numbers were considered in these association 
analyses.
ePiTOPeS AND SeROLOGiCALLY  
CROSS-ReACTiNG GROUPS
Many sera with HLA antibodies exhibit complex reactivity 
patterns that prohibit their use in serological typing. Early 
studies identified sera that reacted with the so-called cross-
reacting groups (CREGs) of HLA antigens; the A2-CREG 
and B7-CREG are common examples (10, 11). Each CREG 
has the so-called public determinants shared between certain 
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groups of antigens and so-called private determinants limited 
to a given serologically defined antigen within the CREG (12). 
Many public determinants correspond to structurally defined 
epitopes. As an example, the A2-CREG, which includes A2, 
A23, A24, A68, A69, and B17, has several epitopes corre-
sponding to public determinants including the 127K eplet on 
A2 + A23 + A24 + A68 + A69, 144TKH on A2 + A68 + A69, 
107W on A2 + A69, and 62GE on A2 + B17, and all of them have 
been antibody verified. It has become evident that all HLA class 
I antigens have public determinants or shared epitopes that can 
be recognized by antibodies.
Although CREG matching has been applied to the identi-
fication of compatible platelet donors for refractory alloim-
munized thrombocytopenic patients (13), no beneficial effect 
could be convincingly demonstrated on transplant outcome 
largely because these studies did not consider individual public 
epitopes. Most highly sensitized patients have antibodies against 
public epitopes that can now be defined structurally.
ePiTOPe-BASeD MATCHiNG 
ReQUiReS DNA-BASeD HLA  
TYPiNG AT THe ALLeLe LeveL
Serological HLA typing had always accuracy problems because 
of the lack of reagents and technical limitations. After elucida-
tion of the HLA molecular structure and nucleic acid sequenc-
ing of HLA antigens during the late 1980s, the application of 
DNA-based technologies permitted accurate HLA antigen 
typing results. Very soon, many antigens were identified with 
amino acid differences, and this led to assignments of alleles 
to be annotated with a colon (:) followed by two and later on 
three digits after more than 100 alleles corresponding to the 
2-digit antigen had been identified (Examples are A*02:01 and 
A*02:101). Certain amino acid differences affect the expres-
sion of eplets. For instance, A*24:02 has the antibody-verified 
166DG eplet shared with A*01:01, A*23:01, A*80:01, and 
B*15:12, whereas A*24:03 has 166EW shared with A*02:01, 
A*03:01, etc. This example illustrates the difficulty of matching 
at the antigen level, in this case A24 if the patient has antibodies 
against 166DG or 166EW. It is now recognized that HLA com-
patibility is better determined at the allele than at the antigen 
level (14).
There are thousands of HLA alleles and the question arises 
which ones should be typed for in the clinical transplant set-
ting. One might focus on alleles present in the patient and 
donor population of a given transplant program. Although rare 
alleles might be excluded it is now apparent that because of the 
increasing racial and ethnic heterogeneity of most populations 
such alleles occur more frequently as mismatches. Tissue typ-
ing techniques are moving forward very fast in the clinical 
setting, and each HLA allele has precise information about its 
eplet repertoire. The degree of eplet mismatching of a donor 
allele depends on the HLA phenotype of the recipient, which 
has its own repertoire of self-eplets. Such determinations can 
be readily made with specifically designed computer programs 
such as HLAMatchmaker.
ANTiBODY ReACTiviTY wiTH HLA 
ePiTOPeS
Epitope-based HLA compatibility determination requires a 
basic understanding of how antibodies interact with epitopes. 
Antibody reactivity testing with HLA panels can be done with 
different techniques from immunoglobulin and complement 
component C1q binding to isolated HLA molecules attached 
to microbeads to flow cytometric binding on lymphocytes and 
complement-dependent lymphocytotoxicity. These methods may 
give different results which make clinical relevance assessments 
difficult. Epitope specificity analyses of antibodies may clarify 
some of these issues.
Antibody binding to protein epitopes occurs through six 
complementarity-determining region (CDR) loops, three of them 
H1, H2, and H3 are on the immunoglobulin heavy chain and L1, 
L2, and L3 are on the light chain. Each loop interacts with a small 
set of amino acid residues in the so-called structural epitope and 
CDR-H3 which binds to the so-called functional epitope (or hot 
spot) in a central location has a dominant role in determining 
antibody specificity. Eplets are considered to be equivalent to 
functional epitopes. Figure  1 shows models of eplets in three 
different locations on class I molecules and in context with cor-
responding structural epitopes and hypothetical contact sites for 
the CDRs of antibody. Two eplets are readily antibody accessible 
on the upper domains (Figures 1A,B), but antibodies to eplets on 
the membrane-proximal domain (Figure 1C) might interact with 
only solubilized but not with lymphocyte membrane-bound HLA 
molecules because these epitopes may not be readily antibody 
accessible. Would such epitopes be clinically significant?
Antibodies through their CDR-H3 recognize specific eplets 
centrally located in the structural epitope. Other eplets in the 
same sequence location but with different residue compositions 
are generally non-reactive, but there can be exceptions if the 
eplet has a high degree of residue homology with the eplet that 
had induced the antibody. As an example, the 82LR eplet, which 
describes the well-known Bw4 epitope, has two closely nearby 
residues 80I and 80T. Many 80I  +  82LR-induced antibodies 
recognize also 80T + 82LR and binding strengths can vary from 
high to low. This is an example of the so-called Landsteiner type 
of serological cross-reactivity, whereby different but structurally 
related epitopes react with the same antibody. It should be noted 
that certain 80I  +  82LR-induced antibodies never react with 
80T + 82LR; they can be designated as specific for only 80I. This 
epitope-based analysis seems helpful in the assessment of the mis-
match acceptability of 82LR (or Bw4) when 80T + 82LR-carrying 
alleles have no or very low reactivity with patient’s serum.
As illustrated in Figure  1, the structural epitope has other 
amino acid configurations that interact with the remaining 
CDRs of antibody. As described in many immunology textbooks, 
an important consideration is the so-called affinity maturation 
process during the antibody response, whereby DNA regions cor-
responding to CDRs undergo mutations which increase antibody 
affinity with the structural epitope. As an example, let us just 
consider for Figure 1A one CDR-loop L2, which as a result of 
affinity maturation, has increased binding with a given amino acid 
FiGURe 1 | Three models of structural HLA class i epitope. The HLA molecule has three components: HLA chain (pink), β2-microglobulin (blue), and the 
bound peptide (green). The centrally located eplet (in pink) interacts with CDR-H3. Residues within a 15-Å radius are colored yellow and include configurations (in 
oval circles) that make contact with other CDRs on heavy chain (H1 and H2) and light chain (L1, L2, and L3). (A–C) reflect three different epitope locations on the 
molecule.
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configuration in the structural epitope of the immunizing allele. 
Two possible configurations can be considered. One comprises 
only monomorphic residues shared between all alleles in the 
panel, and the epitope recognized by antibody corresponds solely 
to an eplet. Second, this configuration has polymorphic residues 
and only alleles that share such residues with the immunizing 
allele are antibody reactive. Such residues represent critical con-
tact sites for antibody. Accordingly, these epitopes can be defined 
by eplets paired with distinct residue configurations (including 
eplets) in other sequence locations within a 15-Å radius, a pre-
sumed dimension of a structural epitope. As an example, there 
are antibodies specific for 82LR paired with 145RA; this epitope 
is present on all 82LR-carrying alleles except A25 and B13 that 
have 82LR + 145RT and 82LR + 145LA, respectively. It should be 
noted that the critical contact residue configurations are almost 
uniformly present on at least one allele of the antibody producer, 
and this suggests an autoimmune component of the antibody 
response to a mismatched eplet.
As illustrated in Figure  1B, some CDRs can make contact 
with peptides bound to the groove, and it is possible that peptides 
serve as critical contact sites for a CDR such as H2. Indeed, it has 
been reported that certain HLA antibodies are peptide dependent 
(15–17).
For many protein antigen–antibody complexes, there is a 
certain level of permissiveness for residue substitutions in criti-
cal contact areas, and this applies also for HLA epitopes. Certain 
residue substitutions in the structural epitope have a moderate 
effect on an allele’s reactivity with antibody, whereas others are 
inhibitory to the level of weak reactivity or non-reactivity of 
specific eplet-carrying alleles. The latter might be considered as 
epitope-based acceptable mismatches.
The same rules apply to epitope descriptions of class II alleles 
which more often solely correspond to eplets. Only few DRB 
epitopes correspond to eplet pairs, and this might be due to 
monomorphic residue nature of the DRA chain. Several immu-
nogenic DRB1 eplets are also on alleles encoded by DRB3, DRB4, 
and/or DRB5. Each of them has distinct antibody-verified eplets, 
and it seems that epitope matching for DRB3/4/5 affects the class 
II antibody response.
DQ and DP encode for heterodimers of A and B chains which 
are both polymorphic and have distinct eplets many of which 
have been antibody verified. DQ-specific antibodies appear most 
prevalent among antibodies induced by class II mismatches. Such 
antibodies are specific for eplets on DQA and DQB chains, and 
there is emerging evidence that some DQ epitopes are defined 
by eplet pairs involving both chains (18, 19). This suggests that 
epitope-based matching should consider the DQ heterodimer 
rather than the individual chains alone. DP mismatching involves 
generally fewer epitopes on DPB and especially on DPA; immu-
nogenic eplets, such as 84DEAV and 55DE, are present on large 
groups of DPB alleles.
RePeRTOiReS OF ANTiBODY-veRiFieD 
HLA ePiTOPeS
Eplets are small configurations of amino acid residues that play 
dominant roles in HLA epitopes reactive with antibodies. Such 
configurations are theoretical considerations based on residue 
differences in polymorphic sequence locations, but we must 
raise the question how many of them are actually recognized 
by specific antibodies. One would expect the clinical relevance 
of epitope-based matching to apply only to epitopes that have 
been experimentally verified with informative antibodies. The 
HLA Epitope Registry has a list of antibody-verified epitopes 
recorded this far for each locus, but the repertoire is still 
incomplete. Very recently, the website includes a downloadable 
PDF file “EpiPedia of HLA” that describes the antibody verifica-
tions of HLA epitopes in detail. With the help of participating 
HLA laboratories that might have interesting serum antibody 
reactivity patterns, we will continue our analyses to identify 
new epitopes. The HLAMatchmaker website www.epitopes.net  
(formerly www.HLAMatchmaker.net) has now a downloadable 
5Duquesnoy HLA Epitope-Based Matching
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Excel document “Five Maps of HLA Epitopia,” which describes 
the sequence locations of antibody-verified eplets and poly-
morphic residues as potential candidates defining additional 
epitopes. These maps can be used in navigating the continents 
of HLA Epitopia while searching for newly antibody-defined 
epitopes (20).
TeCHNiQUe-DePeNDeNT ePiTOPe 
SPeCiFiCiTieS OF HLA ANTiBODieS
The use of C1q-binding and complement-dependent lymphocy-
totoxicity assays has added other dimensions of the complexity 
of the antibody response to a mismatch. These tests are based 
on sequential events following the formation of the antibody–
epitope complex. C1q binding requires a conformational change 
in the antibody molecule, thereby exposing the C1q receptor on 
the Fc part, and complement-dependent cytotoxicity is initiated 
by the activation of antibody-bound C1qrs complex as the first 
step of the classical complement pathway. Both processes require 
free energy released during antibody–epitope complex forma-
tion, and the amount depends on the binding strength between 
all CDRs with the structural epitope. Some antibodies react only 
with the immunizing epitope in Ig-binding assays; this means 
that the amount of free energy release is insufficient for the acti-
vation of complement-dependent mechanisms that contribute 
to inflammatory responses (21, 22). A given antibody can react 
with the immunizing eplet and certain eplet-sharing alleles in the 
panel in all three assays. Other eplet-carrying alleles react only in 
Ig-binding assays, because they lack certain critical residues in 
the corresponding structural epitopes required for strong bind-
ing with antibody required for the initiation of the inflammatory 




The above interpretations about antibody reactivity and epitope 
specificity are more readily made with monospecific sera. 
However, most sera from sensitized patients have mixtures of 
antibodies, and although the reactivity patterns are generally 
limited to a few specificities, there are additional features that 
can make epitope-based interpretations often quite challenging. 
They include unexpected reactivities of certain panel alleles due 
to “natural” antibodies or non-specific blocking factors includ-
ing a prozone effect; sera may also have competing antibodies 
with different characteristics including Ig subtypes. Many sera 
from highly sensitized patients have antibodies reacting with 
high-frequency (i.e., >80%) epitopes, which make detections of 
antibodies against lower frequency epitopes more difficult unless 
these antibodies are separated through absorption–elution stud-
ies with selected alleles.
Technique dependencies of serum reactivity may also affect 
the interpretation of epitope specificities, especially for highly 
sensitized patients who have several antibody populations in dif-
ferent concentrations and affinities that affect their reactivity with 
HLA panels. Again, absorption–elution studies with selected 
alleles might dissect these serum reactivity patterns, so that an 
epitope analysis can be more readily done.
The HLAMatchmaker website has three downloadable antibody 
analysis programs in Excel format: HLA-ABC, HLA-DRDQDP, 
and MICA. The latest 02 versions focus on antibody-verified 
epitopes recorded so far in the HLA Epitope Registry. All of them 
correspond to single eplets or eplets paired with other residue 
configurations uniquely shared by a group of antibody-reactive 
alleles. The antibody analysis programs also include “other” 
theoretical eplets, which might become experimentally verified 
if informative antibodies are identified. The HLAMatchmaker 
website has a downloadable instruction manual for the epitope 
analysis of HLA antibodies tested in assays with single alleles.
The 02 versions require entering of the HLA information of the 
panel, the MFI values of each allele and the allelic HLA type of the 
patient and preferably the immunizer (e.g., a previous transplant 
or in case of a pregnancy, the paternal allele of a child). A calcula-
tion of the MFI for the self alleles offers a basis for determining a 
cutoff value be entered, and the program then determines which 
epitopes are shared between reactive alleles.
In the clinical setting, the primary purpose of the serum 
HLA antibody analysis of transplant candidates is to identify 
potential donors whose mismatched HLA alleles are acceptable. 
This approach is useful not only for organ transplantation but 
also for platelet transfusions of allosensitized thrombocytopenic 
patients. Eurotransplant has incorporated HLAMatchmaker in 
the Acceptable Mismatch Program to identify donors for highly 
sensitized patients (23, 24).
Epitope specificity analyses might also be useful in desen-
sitization protocols to remove donor-specific antibodies (25). 
Such protocols are not always uniformly successful but for some 
patients they may remove some epitope-specific antibodies, 
thereby opening new windows of opportunity regarding the 
identification of selected allelic mismatches.
POSTTRANSPLANT MONiTORiNG  
OF HLA ANTiBODieS
Many posttransplant studies have shown associations between 
the appearance of donor-specific antibodies with allograft rejec-
tion and failure. Most studies have cases whereby the transplant 
continues to function quite well in the presence of donor-specific 
antibodies, and this raises the question which antibodies are clini-
cally significant in transplantation. By definition, such antibodies 
must be absorbed by the allograft where they recognize epitopes 
expressed on the vascular endothelium and other tissues and 
initiate inflammatory processes leading to rejection. Accordingly, 
testing for circulating HLA antibodies in the presence of a 
transplant has its limitations, and this becomes apparent with the 
increased serum reactivity often seen after allograft nephrectomy 
(26–28), and the identification of donor-specific antibodies in 
eluates from surgically removed transplants (29–33). The ques-
tion about epitope specificities of clinically important antibodies 
can be studied in comparative analyses of pre- and post-allograft 
nephrectomy sera and better yet by analyzing antibody reactivity 
patterns of allograft eluates.
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CONTROL OF ANTiBODY ReSPONSeS TO 
HLA ePiTOPeS
HLA matching at the epitope level also benefits transplant 
outcome in non-sensitized patients who have no donor-specific 
HLA antibodies before transplantation. Numerous studies have 
demonstrated significant correlations between eplet loads of 
HLA mismatches and the development of donor-specific class I 
and class II antibodies as well as rejection incidence and allograft 
outcome (34–48). These findings are clinically useful in two ways. 
First, for each transplant, the eplet load can be readily determined 
with special matching programs that can be downloaded from the 
HLAMatchmaker website. The amount of a mismatched epitope 
load can be considered as a risk factor during the posttransplant 
monitoring for antibody-mediated rejection. This information 
seems also useful in clinical protocols to achieve immunological 
tolerance (25).
Second, eplet loads can be used to develop new donor selec-
tion strategies for non-sensitized recipients especially younger 
patients. Some transplant programs have already begun to imple-
ment this approach (49–51). HLA mismatches with low eplet 
loads can be expected to improve transplant outcome. Even if 
the first allograft rejected, retransplant candidates might become 
less highly sensitized, thereby making it easier to find acceptable 
mismatches.
The relative immunogenicity of HLA eplets plays an impor-
tant role in mismatch permissibility of HLA alleles. This can be 
determined empirically by analyzing the frequencies of antibody 
responses to mismatched donor eplets which depend on the HLA 
phenotypes of the recipient and their specificities would be for 
epitopes defined by eplets or eplet pairs (52). Such studies do not 
consider the mechanisms of the antibody response which involves 
the activation of B-cells with epitope-specific Ig-receptors, their 
subsequent proliferation induced by cytokines from helper 
T-cells and the differentiation including affinity maturation into 
antibody-producing plasma cells.
Three recent concepts have begun to address these mechanisms. 
First, the non-self–self paradigm of HLA epitope immunogenic-
ity is based on the hypothesis that HLA antibodies originate 
from B-cells with low-avidity, self-HLA epitope-specific Ig-type 
receptors that can interact with non-self eplets to generate a signal 
for B-cell activation. Such non-self eplets would be recognized by 
the specificity-determining CDR-H3, and in the context of the 
corresponding structural epitope they must be surrounded by 
self-residues that contact the other CDRs of antibody (53–56). 
Second, Kosmoliaptsis et  al. have proposed that the relative 
antigenicity of an eplet can be predicted from the physiochemical 
properties of its amino acid residues (57–59). Accordingly, the 
electrostatic difference between a non-self eplet and a self-eplet 
might provide the trigger for B-cell activation (60). Third, 
activated B-cells need T-cell help for their proliferation and 
differentiation into antibody-producing plasma cells. The group 
of Eric Spierings has proposed the so-called PIRCHE-II concept 
(i.e., Predicted Indirectly ReCognizable HLA Epitopes presented 
by HLA-DRB1), whereby helper T-cells release cytokines upon 
recognition of DRB-presented mismatched HLA peptides gener-
ated after processing of Ig receptor–allele complexes taken up 
by activated B-cells (61, 62).
These are reasonable theoretical concepts, although no direct 
experimental methods are available to analyze the very early 
phases of the antibody response (63). At present, we can only 
use indirect approaches, such as serum antibody specificity 
analysis, molecular assessments of matching, and structural 
analysis of HLA-antigen–antibody complexes, to study the 
immunogenicity of HLA epitopes. It is important to know a 
complete repertoire of antibody-verified epitopes. Such inves-
tigations could lead to a better understanding of HLA epitope 
immunogenicity, and how this can be applied to permissible 
mismatch strategies.
CONCLUSiON
Epitope-based HLA matching has become a new concept in the 
clinical transplant setting. It relies on HLA typing at the allele 
level and can be used to identify acceptable mismatches for sen-
sitized patients and to develop permissible mismatch strategies 
for non-sensitized patients. Our understanding of HLA epitopes 
is still in progress, and more studies are needed to identify 
antibody-verified epitopes to be recorded in the HLA Epitope 
Registry. Also, histocompatibility testing laboratories will have 
opportunities to sort out complex serum reactivity patterns 
and interpret technique-dependent epitope specificities of HLA 
antibodies and their clinical relevance. Sooner or later, there will 
be new epitope-based HLA-matching approaches with increased 
benefits to transplant patients.
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